Infection Preventionist Role in Antimicrobial Stewardship

EMILY SICKBERT-BENNETT, PHD, MS, CIC, FSHEA DIRECTOR OF INFECTION PREVENTION ADMINISTRATIVE DIRECTOR OF ANTIMICROBIAL STEWARDSHIP PROFESSOR OF MEDICINE/INFECTIOUS DISEASES ASSOCIATE PROFESSOR OF EPIDEMIOLOGY



Call to Action:

The Threat of Antibiotic Resistance in the United States

Antibiotic resistance—when germs (bacteria, fungi) develop the ability to defeat the antibiotics designed to kill them—is one of the greatest global health challenges of modern time.

New National Estimate*

Each year, antibiotic-resistant bacteria and fungi cause at least an estimated:











Antibiotic Resistance Threats in the United States, 2019 (cdc.gov)

CDC strategies that work in healthcare:



Preventing device- and procedurerelated infections, such as from urinary catheters or central lines



Stopping the spread of resistant germs within and between healthcare facilities



Containing emerging threats through early detection and aggressive response



Tracking and improving appropriate antibiotic use



Infection prevention and control in non-hospital settings, such as long-term care facilities

Infection Prevention

Infection Prevention

Infection Prevention

Infection Prevention

<u>Antibiotic Resistance Threats in</u> <u>the United States, 2019 (cdc.gov)</u>

Antimicrobial Stewardship Infrastructure

- Pharmacists
- Infectious disease physicians
- Laboratorians
- Quality Improvement Specialists
- Analysts/Epidemiologists
- Program Managers



Infection Prevention Infrastructure

- Infection Preventionists
- Infectious disease physicians
- Laboratorians
- Quality Improvement Specialists
- Analysts/Epidemiologists
- Program Managers



STOP THE SPREAD

Infection prevention and control to stop the spread of antibiotic resistant organisms is an essential part of effective antimicrobial stewardship.

STEWARDSHIP IS A TEAM SPORT

Stewards work together with pharmacy, microbiology, infection prevention, information technology, executives, front-line clinicians, and others to optimize antibiotic use. The development and refinement of local guidelines and care pathways can be considered part of the teamwork that stewards do.

ESSENTIAL ROLE OF MICROBIOLOGY

A hallmark of antimicrobial stewardship is helping clinicians obtain an accurate diagnosis.

USE IT AND LOSE IT

Resistance is predictable and antibiotic overuse is directly linked to the development of antibiotic resistance.



USE WHAT YOU NEED, AND NOTHING MORE

Antibiotic stewardship means optimizing antibiotics. Use the right drug for the right patient for the right indication at the right dose for the right duration.

惩IDSA

Clinical Infectious Diseases



The Impact of Antibiotic Stewardship Program Resources on Infection Prevention Programs

Susan C. Bleasdale,^{1,0} Marsha Barnden,² and Sue Barnes³

¹University of Illinois, College of Medicine; ²Adventist Health, Roseville, California and ³Independent Clinical Consultant, San Mateo, California

Doernberg and colleagues describe the role and resourcing of the infectious disease (ID) physician for an effective hospital-based antibiotic stewardship program (ASP). There are similar resource requirements for the ID physician leader in an effective infection prevention (IP) program. This ID physician partnership is supported by professional organizations and predates the imperative of ID physician leadership in ASP. There are regulatory requirements for stabilished IP programs, but they do not specify leadership structure to the same degree as ASP regulations. The Centers for Medicare and Medicaid and The Joint Commission have specified the inclusion of an ID-trained physician leader in ASP, and this has led to the development of curriculum to train more ASP physicians. More robust advocacy may ensure a similar regulatory mandate supporting the participation of ID-trained physicians in IP programs. This may encourage the development of a curriculum to meet the workforce.

Keywords. infection prevention; resources; antimicrobial stewardship; infection prevention curriculum; infectious disease workforce.

Antimicrobial Stewardship Core Elements

Core Elements of Hospital Antibiotic Stewardship Programs



Hospital Leadership Commitment Dedicate necessary human, financial, and information technology resources.

Accountability

Appoint a leader or co-leaders, such as a physician and pharmacist, responsible for program management and outcomes.



Pharmacy Expertise (previously "Drug Expertise"):

Appoint a pharmacist, ideally as the co-leader of the stewardship program, to help lead implementation efforts to improve antibiotic use.

Action

Implement interventions, such as prospective audit and feedback or preauthorization, to improve antibiotic use.

Tracking

Monitor antibiotic prescribing, impact of interventions, and other important outcomes, like *C. difficile* infections and resistance patterns.

Reporting

Regularly report information on antibiotic use and resistance to prescribers, pharmacists, nurses, and hospital leadership.

Education

Educate prescribers, pharmacists, nurses, and patients about adverse reactions from antibiotics, antibiotic resistance, and optimal prescribing.

https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf

Infection Preventionist Core Elements

Mission

• To promote a safe and healthy environment through the prevention of healthcare-associated infections in patients and the transmission of infectious diseases among patients, personnel, and visitors, and to contribute to infection prevention research to guide evidence-based practices

Strategies

- Develop, update, and implement evidence-based **infection prevention policies** and protocols to ensure the safety of staff, patients, and visitors
- Monitor and **disseminate infection-related data**
- Promote continuous quality improvement by leveraging **multidisciplinary workgroups** to develop, implement, and share strategies to prevent HAIs
- Provide **education** to empower the HCP workforce and patients to prevent HAIs and protect themselves from communicable disease
- Conduct routine infection prevention compliance rounding
- Conduct communicable disease exposure and outbreak investigations
- Provide **consultation** to external departments regarding infection risk assessment, prevention, and control strategies







Tracking and

Reporting

SURVEILLANCE FOR HEALTHCARE-ASSOCIATED
 INFECTIONS

• TREND ANALYSES OF ANTIMICROBIAL USE

Hospital-associated *C.difficile* infection rates



Meropenem Use 2017-2023





Education

i 🚖 🛞 Shorter. Safer. Better.

Thank you for pledging to use the shortest effective durations of antimicrobial therapy with your patients.

Scan the QR code to view best practice

🔭 TAKE THE SHORTER. SAFER. BETTER. PLEDGE

CASP team members and allies have signed on to the Shorter. Safer. Better. pledge to demonstrate their personal commitment to know, use, and share the shortest effective antimicrobial durations in their practice. Please consider joining us.

"I pledge to preserve antibiotics and do what is best for my patients by incorporating the shortest appropriate duration of antimicrobials into my practice. I will further action this commitment by..."[read more & take the pledge. UNC login required.]



Take the Pledge

Print and share 🔀 the Shorter. Safer. Better. flyer.

See a list of those who have taken the pledge.

Examples of Shorter. Safer. Better. In Action

C: Acute Bronchitis Situation: A 35-year-old patient with acute bronchitis presents to an outpatient **Urinary Tract Infection** Situation: A four-year-old female patient is admitted for pyelonephritis. Urine culture is Community-Acquired Pneumonia Situation: A 65-year-old patient presents to the Emergency Department with

Reported Use of Shorter Antimicrobial Durations at Time of Pledge and 90-days Post-Campaign



Action

- TIME-OUTS AND HANDSHAKE STEWARDSHIP
- DEVICE STEWARDSHIP ROUNDS AND REAL-TIME
 AUDIT AND FEEDBACK

Antibiotic Time Outs

Created By: Michael Swartwood, BSN, RN, CAPM

| | Current Services (Month of Adoption): MDA (11/18) HBD (2/19), HBC (2/19), Family Medicine Blue (4/19) Family Medicine Green (4/19) PMB (11/19) PMA | | Percent of Time Outs Within Time Limits Goal: 80% | | | | |
|--|--|---------------|--|---------|------|-----------|---|
| | (1/20), PICU (6/20), Family Medicine Teal (7/21), BICU (8/21) | | MDA | FAM MED | HBC | PMA + PMB | |
| | 0.211 | July 16, 2022 | 100% | 88% | 100% | 100% | 1 |
| | Total Patients Evaluated | July 9, 2022 | 80% | 100% | 50% | 100% | 1 |
| | 3,714 Total Time Outs Conducted 942 Total Time Outs With Recommendations for Change | July 2, 2022 | 100% | 100% | | 50% | 1 |
| | | June 25, 2022 | 100% | 90% | | 90% | 1 |
| | | June 18, 2022 | 80% | 92% | | 100% | |
| | | June 11, 2022 | 100% | 89% | | 60% | |





 Remove nonessential catheters (Quality of Evidence: MODERATE)

- a. Assess the need for continued intravascular access on a daily basis during multidisciplinary rounds. Remove catheters not required for patient care. Decreasing CVC utilization reduces CRBSI risk.¹⁵⁹ However, reducing CVC utilization may result in increased use of other intravascular catheters with corresponding infection risk.
- b. Audits to determine whether CVCs are routinely removed after their intended use may be helpful.^{160,161} Both simple and multifaceted interventions are effective at reducing unnecessary CVC use.^{162,163}

Infection Control & Hospital Epidemiology (2022), 43, 553-569 doi:10.1017/ice.2022.87 **SHEA**

SHEA/IDSA/APIC Practice Recommendation

Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update

Niccolò Buetti MD, MSc, PhD^{1,2,a}, Jonas Marschall MD, MSc^{3,4,a}, Marci Drees MD, MS^{5,6}, Mohamad G. Fakih MD, MPH⁷, Junn Hadaway MEd, RN, NPD-BC, CRNI⁸, Lisa L. Maragakis MD, MPH⁹, Elizabeth Monsees PhD, MBA, RN, CIC^{10,11}, Shannon Novosad MD MPH¹², Naomi P. O'Grady MD¹³, Mark E. Rupp MD¹⁴, Joshua Wolf MBBS, PhD, FRACP^{15,16}, Deborah Yokoe MD, MPH¹⁷ and Leonard A. Mermel DO, ScM^{18,19}

Percent of Eligible Patients With a Time Out Goal: 80%

| | MDA | FAM MED | HBC | PMA+PMB | PICU | BICU |
|------|------|---------|------|---------|------|------|
| 022 | 100% | 88% | 100% | 5096 | 100% | |
| 22 | 100% | 100% | 100% | 100% | 100% | |
|)22 | 100% | 100% | 096 | 100% | 100% | |
| 022 | 50% | 90% | 096 | 100% | 100% | |
| :022 | 100% | 92% | | 100% | 100% | |
| 022 | 67% | 89% | | 100% | | |



"We'VE RUN THE WHOLE GAMUT OF TESTS ON YOU, AND YOU NOW APPEAR TO BE SUFFERING FROM OVERTESTING."

Diagnostic Stewardship

Box 1. Reasons to Focus Diagnostic Stewardship on Blood, Urine, and Respiratory cultures, and Clostridioides difficile Testing

Blood cultures

- · One of the most commonly ordered microbiologic tests in hospitalized patients with low positivity and high risk of false-positive results (up to half of all positive blood cultures represent contaminants)
- · A significant number of blood cultures are collected as single blood cultures and/or with inappropriate blood volume.
- · Inappropriate testing may overestimate central-line-associated bloodstream infections (CLABSIs).

Urine cultures

- · One of the most common drivers of inappropriate antimicrobial use in hospitalized patients
- Common clinical false-positive results (positive tests due to colonization) without UTI)
- Inappropriate testing may overestimate catheter-associated urinary tract infections (CAUTIs).

Respiratory cultures

- High risk of positive results representing colonization, especially among patients with comorbidities, in the intensive care unit, or with tracheostomy
- · Common driver of inappropriate antibiotic use in hospitalized patients

C. difficile testing

- · Inappropriate testing may detect colonization and expose patients to unnecessary antibiotics.
- Inappropriate testing may overestimate nosocomial C. difficile cases.

Infection Control & Hospital Epidemiology (2023), 44, 178-185 doi:10.1017/ice.2023.5

SHEA

SHEA Position Paper

Principles of diagnostic stewardship: A practical guide from the Society for Healthcare Epidemiology of America Diagnostic Stewardship Task Force

Valeria Fabre MD¹ (0), Angelina Davis PharmD² (0), Daniel J. Diekema MD³, Bruno Granwehr MD⁴, Mary K. Hayden MD⁵, Christopher F. Lowe MD⁶ O, Christopher D. Pfeiffer MD⁷, Anna C. Sick-Samuels MD⁸ O, Kaede V. Sullivan MD⁹ O,

Trevor C. Van Schooneveld MD¹⁰ in and Daniel J. Morgan MD¹¹

¹Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States, ²Duke University, Durham, North Carolina, ³Department of Medicine, University of Iowa, Iowa City, Iowa, United States, ⁴Department of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, Texas, United States, ⁵Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, United States, ⁶Division of Medical Microbiology and Virology, Providence Health Care, Vancouver, Canada, ⁷VA Portland Health Care System, Oregon Health & Science University, Portland, Oregon, United States, ⁸Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States, ⁹Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States, ¹⁰Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States and ¹¹Department of Epidemiology and Public Health, University of Maryland School of Medicine and VA Maryland Healthcare System, Baltimore, Maryland, United States

| | Inappropriate Test Use | Potential Consequences of Inappropriate Testing | |
|--|---|---|-----------------------------|
| | Routine ordering of microbiologic tests when specimens are obtained for non-infectious indications | Overdiagnosis. Treatment of contaminant or colonizing organisms, Excess cost. Increased length of stay. Increased test utilization to confirm negative. | Infection Prevention |
| | Unnecessary pre-operative urine cultures | Overdiagnosis. Unnecessary antibiotic prescribing | |
| | Urine and respiratory cultures for test of cure or asymptomatic patients | Overdiagnosis. Unnecessary antibiotic prescribing | |
| | Urine cultures for change in mental status or nonspecific | Missed diagnosis. Missing true reason for presenting symptom | |
| | symptoms | Overdiagnosis. Unnecessary antibiotic prescribing, additional catheter-associated urinary tract infection (CAUTI) events | Infection Prevention |
| | C. difficile testing in patients on laxatives or previously positive | Overdiagnosis. Unnecessary antibiotic prescribing, additional C. difficile lab ID events | Infection Preventior |
| | β-D-glucan to exclude mucormycosis | Missed diagnosis. Inadequate antimicrobial management | |
| | Recurring blood cultures in patient with known cause of fever | Overdiagnosis. Unnecessary antibiotics. | |
| | | Patient comfort. Unnecessary procedures. Healthcare-associated anemia | Infection Prevention |
| | Single blood cultures in adults | Missed diagnosis. Inadequate antimicrobial management. | |
| | | Overdiagnosis. Treatment of contaminants. | Infaction |
| | Superficial wound swabs for culture | Missed diagnosis. Missing the true pathogen | Prevention |
| | | Overdiagnosis. Unnecessary antibiotic prescribing | |
| | Routine use of SARS-CoV-2 PCR to determine duration of isolation | Overdiagnosis. Unnecessary prolonged isolation | |

on

on





Education on how to use diagnostics judiciously

- Urinalysis
 - Pyuria has excellent negative predictive value (no pyuria=no UTI)
 - Presence of pyuria: does not signify need to treat
- Urine culture
 - Bacteriuria does not need to be treated if no urinary symptoms
- Respiratory culture
 - Send for patients with severe community-associated pneumonia/inpatients treated empirically for MRSA or Pseudomonas, ventilator-associated pneumonia
 - Positive respiratory culture
 - Decide if presence of pneumonia based on symptoms/clinical picture
- C. difficile testing
 - Send C. *difficile* testing only if pretest probability is moderate/high
- Wound cultures
 - Often represent colonization

Asymptomatic bacteriuria

DO I REALLY NEED TO TREAT MY PATIENT FOR A UTI? TREATING ASYMPTOMATIC BACTERIURIA HAS NO BENEFITS AND CAUSES HARM. IN FACT, IT LEADS TO AN INCREASE IN... Antibiotic C diff infections resistance No UA Needed

Misclassification Healthcare costs Length of stay of CAUTI **MY PATIENT IS SICK** Send UA AND I SUSPECT A UTI • Odor Frequency Color SHOULD I TEST? Burning • Altered mental status **alone** Pain UA is only helpful for predicting • Fever or leukocytosis UTI among patients with without urinary symptoms appropriate urinary symptoms WHAT IS THE BEST 4 WAY TO TEST? 2 Order urine culture Order a UA if only if UA+ Treat based on Interpret UA symptomatic culture results 3

Adult UTI Guideline Update

4 New Algorithms









Diagnosis

· Painful urination

Altered Mental Status Treatment **Urine Culture** Interpretation

Inappropriate urine cultures Reserve UTI diagnostic workup for those with UTI symptoms: pose harm to patients

- New or worsening urinary frequency or urgency
- Suprapubic pain
- Flank pain or tenderness

Bladder Infection or Cystitis

UNC 1st line options: Nitrofurantoin

 Bactrim (SMX-TMP) Ciprofloxacin does NOT cover 1 in 3 E. coli isolates at UNCMC





Misdiagnosis

Pyelonephritis



 Ceftriaxone Gentamicin

> Target therapy to cultures & use shortest effective duration

Learn more at https://uncmedicalcenter.intranet.unchealthcare.org/dept/Epidemiology/Pages/CAUTI-Prevention-Initiative.aspx

Blood Culture **Best Practices**



BLOOD CULTURE BEST PRACTICES IN ADULTS 2023 Update | UNC Hospitals



- Suspected sepsis
- New fever in ICU patient
- Suspected endocarditis
- · Fever in a neutropenic
- patient
- Suspected
- bacteremia/fungemia
- "Test of cure" >48 hours after the initiation of appropriate antimicrobial therapy is routinely recommended for patients with the following pathogens:
 - Carbapenem-resistant Enterobacteriaceae
 - Enterococcus species
 - Candida species
 - Staphylococcus aureus (MRSA or MSSA)
- Staphylococcus lugdunensis
- · For patients with other pathogens who are clinically improving, evidence is weak that a test of cure improves outcomes.

Think Twice

Blood cultures may not be needed in conditions with low probability for bacteremia (such as post-op fever within 48 hours in clinically stable patients, isolated fever, patients with non-

In a neutropenic patient, routine serial blood cultures in a stable patient with persistent fevers



cultures.

therapy.

venipunctures for the lowest rate of false positive

Use strict aseptic technique.

 Always obtain at least 2 sets of blood cultures, filling each bottle to the recommended 8-10 ml for accurate results.

Obtain blood cultures PRIOR

to initiating antibiotic

DO NOT

- Obtain blood cultures via a peripheral intravenous catheter (PIV) or arterial catheter, even when the catheter is newly placed. This is associated with false positives.
- Obtain a single blood sample and then split the blood among multiple blood culture sets.
- Obtain blood cultures in an asymptomatic patient unless the cultures are being obtained as a "test of cure" for an indicated pathogen as listed above.
- · Obtain blood cultures via central venous catheter if possible (higher risk for contamination). If not feasible to obtain two sets of blood cultures by separate peripheral venipunctures or if trying to salvage the line, obtain one set from the peripheral venipuncture and one from the central line.

UNC Medical Center's Stop Healthcare-associated Infections in Everyone (SHINE - 984-974-7500) & the Carolina Antibiotic Stewardship Program (pager 216-2398). View the guideline: https://go.unc.edu/bloodcx HEALTH-



Testing for C. diff when not indicated can harm your patient





Unnecessary antibiotics (and side effects)



Avoidable

isolation



Increased

lengths of stay

When should I test my patient for C. diff?

- ≥3 liquid stools within 24 hours, without another known medical reason
- No laxatives within past 48 hours*

*If patient has unexplained fever, abdominal pain, AND leukocytosis, testing may be indicated.

Follow Epic process instructions for timing after previous tests.

Testing not recommended for patients under age 2.

C. difficile **Diagnostic Stewardship**



Visit the C. diff page on the Intranet (under Infection Prevention) for more info

| . Difficile Assay | | ✓ <u>A</u> ccept × <u>C</u> ancel | |
|---|--------------------------|--|---|
| * C. Diff Information | Frequency: | Once Once STAT Tomorrow AM Daily | QUALITY IMPROVEMENT |
| Laxatives Ordered Dose/Rate, Route, Frequency bisacodyL (DULCOLAX) EC tablet 5 mg dogueste codium (COLACE) cancula 100, 100 mg, Oral, Daily PRN dogueste codium (COLACE) cancula 100, 100 mg, Oral, Daily | it | At 2/25/2022 🚵 Today Tomorrow 1019 🔊 | C. difficile test ordering: "hard stop" |
| mg at 07/24 15: C Diff Results (Last 14 days) | Has the patient h | ad >=3 liquid stools in the past 24 hour period? | |
| No procedures found | Is the patient on t | reatment for C. difficile? | |
| | • You MUST reques | t Infectious Diseases approval before signing this order. Did Infectious Diseases approve this order? Yes No | ✓ <u>Accept</u> × <u>C</u> ancel |
| | Specimen Type: | Stool P | Frequency: Once Once STAT Tomorrow AM Daily |
| | Specimen Source | Stool 🔎 | At 2/25/2022 🖄 Today Tomorrow |
| | Add-on: | No add-on specimen found Add Comments | |
| | Process Instructions: | "Testing for C. difficile infection is appropriate in patients >= 2 years of age with >= 3 liquid stools in a 24 hour period. Do NOT test if patient: has received laxatives in the past 48 hours"; had a negative C. difficile test in the past 7 days with no NEW symptoms"; had a positive test in the past 14 days; is still on treatment for C. difficile; has finished treatment for C. difficile, in order to demonstrate a "cure". | Has the patient had >=3 liquid stools in the past 24 hour period? Yes No Is the patient on treatment for C. difficile? Yes No You MUST request Infectious Diseases approval before signing this order. Did Infectious Diseases approve this order? |
| | Phase of Care: | | Please indicate who approved this order and when: |
| | | | Specimen Stool Type: Specimen Source: Add-on: No add-on specimen found |
| 🕀 You car | not sign the | se orders because information is missing | or requires your attention: |

C. Diff testing is not currently indicated for this patient. If after review of the C Diff ordering guidelines, you still need to place the order, contact your designated approval point person and document the name and the date of contact in the C Diff order

~

QUALITY IMPROVEMENT *C. difficile* test ordering: "hard stop"

- Total tests orders dropped 15.5% from 1,129 during the same period in 2021 to 954 during the study period (95%CI: 13.4-17.7%).
- Compliance with the guideline component requiring at least a 48-hour laxative-free interval prior to CDI testing increased from 85% (95%CI: 83-87%) to 95% (95%CI: 93-96%).
- CDI incidence rates decreased from 0.52 per 1,000 patient-days (95%CI: 0.41-0.65) to 0.41 (95%CI: 0.32-0.53), though the change was neither significant at p=.05 nor attributable to any one intervention.
- No adverse patient outcomes or empiric antibiotic use.

Outbreak Investigation/ Keeping an Open Mind

- Longitudinal, observational, single-center study, we collected 3,952 rectal swab and stool samples ٠ from 1,289 unique ICU admissions; 425 C. difficile isolates were whole-genome sequenced.
- The integrated genomic, microbiological and epidemiological analyses found that **only 1% (6 of 584)** of eligible patients admitted to the ICU during the study period had genomically supported acquisition of toxigenic C. difficile via cross-transmission.
- 24-times increased risk for developing CDI during hospitalization among patients colonized with toxigenic C. difficile on admission.
- These data suggest that interventions focused on preventing transition from colonization to overt infection will have a greater impact on further reducing the risk of CDI in this setting than investing additional resources aimed at interrupting cross-transmission.

Arianna Miles-Jav¹, Evan S. Snitkin @¹² . Michael Y. Lin³, Teppei Shimasak

Michael Schoeny @³, Christine Fukuda³, Thelma Dangana³, Nicholas Moore @⁴

Sarah E. Sansom 3, Rachel D. Yelin³, Pamela Bell³, Krishna Rao², Micah Keidar Alexandra Standke², Christine Bassis², Mary K. Hayden³ & Vincent B. Young

nature medicine

ceived: 2 August 2022

ccepted: 17 August 2023

blished online: 18 September 202

difficile in an intensive care unit

Collaboration Opportunities

Table 1 Opportunities for future collaboration between ASPs and IPPs

| Low-hanging fruit | Moderate-hanging fruit | High-hanging fruit |
|---|---|---|
| Solidify plans for regular senior leadership access by ASPs in collaboration with IPPs | Refine and enhance data tracking and reporting by ASPs, including NHSN reporting | Consider enhanced models for ID physician recruitment, training and certification in Hospital Epidemiology/Infection Prevention and Antimicrobial Stewardship |
| Utilize infrastructure for telecommunication that was enhanced during the pandemic for future ASP-IPP collabora- tions | Create collaborative ASP-IPP business plans (e.g. adoption of third party software platforms, enhancing access to IT support) | Consider new combined ASP-IPP program models incorporat- ing streamlined command and reporting structures |
| Utilize infrastructure that was created for data access, report- ing and collaboration during the pandemic for future ASP- IPP collaborations | Collaborate on enhancing access to IT, microbiology, nursing staff | Collaborate on providing bundled ASP-IPP telehealth services to other hospitals |
| | Collaborate on patient and staff education | |

Curr Infect Dis Rep (2021) 23: 15 https://doi.org/10.1007/s11908-021-00759-w

HEALTHCARE ASSOCIATED INFECTIONS (G BEARMAN AND D MORGAN, SECTION EDITORS)

Check for

Infection Prevention and Antimicrobial Stewardship Program Collaboration During the COVID-19 Pandemic: a Window of Opportunity

Mariam Assi¹ · Salma Abbas² · Priya Nori³ · Michelle Doll⁴ · Emily Godbout⁴ · Gonzalo Bearman⁴ · Michael P. Stevens⁴ ·

Accepted: 13 July 2021 / Published online: 18 August 2021 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 Collaboration Opportunities: Low-hanging fruit



- Recognize analogies in work activities
- Prepare integrated story-telling of IP and ASP initiatives
- Present updates at each other's committee meetings
- Share semi-annual reports with respective senior leaders
- Collaborate on analytics, surveillance and reporting of outcomes and process measures
- Share information technology resources and consultants for preparing data reports
- Develop coordinated patient and staff educational materials (e.g., diagnostic stewardship)
- Provide cross-training opportunities for physician trainees and nurses

QUESTIONS?

ACKNOWLEDGEMENTS:

CAROLINA ANTIMICROBIAL STEWARDSHIP TEAM

- DANIELLE DOUGHMAN
- NICK MAVROGIORGOS

FOR MORE INFORMATION, VISIT <u>HTTPS://WWW.MED.UNC.EDU/CASP/</u>



References

- Antibiotic Resistance Threats in the United States, 2019 (cdc.gov)
- IDSA Antimicrobial Stewardship Curricula (idsociety.org)
- Bleasdale SC, Barnden M, Barnes S. The Impact of Antibiotic Stewardship Program Resources on Infection Prevention Programs. Clin Infect Dis. 2019 Jul 18;69(3):552-553. doi: 10.1093/cid/ciy986. PMID: 30462184
- <u>https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf</u>
- Fabre V, Davis A, Diekema DJ, Granwehr B, Hayden MK, Lowe CF, Pfeiffer CD, Sick-Samuels AC, Sullivan KV, Van Schooneveld TC, Morgan DJ.
 Principles of diagnostic stewardship: A practical guide from the Society for Healthcare Epidemiology of America Diagnostic Stewardship Task Force. Infect Control Hosp Epidemiol. 2023 Feb;44(2):178-185. doi: 10.1017/ice.2023.5. PMID: 36786646.
- Ku TSN, Al Mohajer M, Newton JA, Wilson MH, Monsees E, Hayden MK, Messacar K, Kisgen JJ, Diekema DJ, Morgan DJ, Sifri CD, Vaughn VM. Improving antimicrobial use through better diagnosis: The relationship between diagnostic stewardship and antimicrobial stewardship. Infect Control Hosp Epidemiol. 2023 Sep 4:1-8. doi: 10.1017/ice.2023.156. Epub ahead of print. PMID: 37665212.
- Miles-Jay A, Snitkin ES, Lin MY, Shimasaki T, Schoeny M, Fukuda C, Dangana T, Moore N, Sansom SE, Yelin RD, Bell P, Rao K, Keidan M, Standke A, Bassis C, Hayden MK, Young VB. Longitudinal genomic surveillance of carriage and transmission of *Clostridioides difficile* in an intensive care unit. Nat Med. 2023 Sep 18. doi: 10.1038/s41591-023-02549-4. Epub ahead of print. PMID: 37723252.
- Assi M, Abbas S, Nori P, Doll M, Godbout E, Bearman G, Stevens MP. Infection Prevention and Antimicrobial Stewardship Program Collaboration During the COVID-19 Pandemic: a Window of Opportunity. Curr Infect Dis Rep. 2021;23(10):15. doi: 10.1007/s11908-021-00759-w. Epub 2021 Aug 18. PMID: 34426728; PMCID: PMC8374122.